5,838 Shares in Novo Nordisk A/S $NVO Acquired by Mainstay Capital Management LLC ADV

Mainstay Capital Management LLC ADV acquired a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 5,838 shares of the company's stock, valued at approximately $403,000.

Several other institutional investors have also recently bought and sold shares of NVO. Kingstone Capital Partners Texas LLC raised its position in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock valued at $690,560,000 after purchasing an additional 10,001,898 shares during the last quarter. Nuveen LLC bought a new position in Novo Nordisk A/S in the 1st quarter valued at $370,272,000. Amundi raised its position in Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company's stock valued at $331,576,000 after purchasing an additional 1,627,051 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Novo Nordisk A/S by 15,919.9% during the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock worth $72,523,000 after acquiring an additional 1,038,137 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Novo Nordisk A/S by 118.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,594,544 shares of the company's stock worth $110,725,000 after acquiring an additional 864,579 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on NVO shares. Rothschild Redb upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 16th. Hsbc Global Res raised Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 1st. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Novo Nordisk A/S in a research report on Saturday, September 27th. Finally, BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average target price of $77.50.

Novo Nordisk A/S Trading Up 1.0%

NYSE NVO opened at $59.63 on Thursday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $120.56. The company has a market cap of $266.25 billion, a price-to-earnings ratio of 16.38, a price-to-earnings-growth ratio of 2.64 and a beta of 0.68. The business's fifty day moving average is $55.03 and its 200 day moving average is $63.45.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were given a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's payout ratio is presently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.